Balchem

Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment comprises nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The Industrial Products segment refers to certain derivatives of choline chloride which manufactured and sold into industrial applications as a component for hydraulic fracturing of shale natural gas wells. The company was founded in January 1967 and is headquartered in Montvale, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Balchem reports record 2022 earnings, eyes growth amid challenges

Balchem's strong performance in 2022, driven by record sales and earnings, positions them well for future growth. Strategic acquisitions and market studies provide opportunities for expansion despite temporary challenges.

Balchem reports record Q1 revenues, navigates market challenges strategically

Balchem's Q1 2023 performance reflects solid financial results, operational efficiency, and progress in sustainability initiatives.
Despite market challenges, the company showcased resilience, innovation, and a strategic focus on long-term growth.
Opportunities for growth and differentiation exist through market expansion, product innovation, and continued sustainability efforts.
Balchem's strong financial foundation, coupled with a commitment to sustainability, underpins its strategic positioning for future success.

Balchem reports stable Q2 earnings, eyes growth in nutrition sector

Balchem delivered a mixed performance in Q2 2023 with revenue decline but improved profitability metrics.
The company faces challenges in revenue growth and leadership transition but maintains financial stability.
Opportunities lie in exploring new markets, leveraging cash reserves, and capitalizing on manufacturing investments.

Balchem (BCPC) reports solid Q3 results amid market challenges

Balchem's Q3 performance reflects resilience amidst challenges, with a focus on innovation, quality, and operational efficiency.
While facing market uncertainties and higher interest expenses, the company's strategic strengths in key segments position it for growth.
Opportunities lie in leveraging partnerships, consumer awareness efforts, and strategic initiatives to drive future sales and profitability.

Balchem reports record earnings in Q4 2023, eyes growth opportunities

Balchem's Q4 2023 performance showcased resilience with record earnings and strong profitability despite challenges in certain segments. Strategic initiatives and focus on sustainability and growth areas like Human Nutrition & Health position the company well for future success. Optimism for 2024 and potential partnerships signal a promising outlook for Balchem.

Balchem reports robust Q1 earnings, focuses on growth strategies

Balchem's Q1 2024 performance reflects strong financial results, driven by record sales and adjusted EBITDA, despite challenges in specific segments.
The company's focus on sustainability, marketing initiatives, and margin improvement positions it well for future growth and market expansion.
Addressing challenges in the Animal Nutrition & Health segment while leveraging opportunities in key segments like Human Nutrition & Health is crucial for sustained success.
Balchem's strategic partnerships, marketing efforts, and participation in investor conferences signal a proactive approach to driving growth and enhancing shareholder value.

Balchem reports solid Q2 earnings, eyes growth amid segment challenges

Balchem's Q2 2024 performance reflects resilience and growth, particularly in the Human Nutrition & Health and Specialty Products segments, despite challenges in the Animal Nutrition & Health segment.
The company's focus on innovation, debt reduction, and operational efficiency positions it well for future opportunities and sustained financial strength.
With a solid financial foundation, Balchem is poised to navigate challenges, capitalize on growth opportunities, and drive value for shareholders in the coming quarters.

Balchem (BCPC) reports record earnings, eyes growth amid margin challenges

Balchem (BCPC) delivered strong financial results in Q3 2024, driven by solid performance across its segments and successful new product launches. While anticipating margin moderation, the company remains optimistic about continued growth opportunities, especially in key segments. Balchem's focus on strategic investments and market stability positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health and Specialty Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment consists of nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The company was founded in January 1967 and is headquartered in Montvale, NJ.

NEW HAMPTON, N.Y., April 15, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, April 29th at 11:00 AM Eastern Time (ET) to review first quarter results. Ted Harris, Chairman of the Board, CEO and President and Martin Bengtsson, CFO will host the call.

Balchem Corporation Announces Quarterly Conference Call for First Quarter Financial Results on April 29, 2022

Balchem Corporation (BCPC) CEO Ted Harris on Q4 2021 Results - Earnings Call Transcript

NEW HAMPTON, N.Y., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today fourth quarter net earnings of $24.9 million for 2021, compared to net earnings of $22.2 million for the fourth quarter 2020. Fourth quarter adjusted net earnings(a) were $27.8 million, compared to $26.9 million in the prior year quarter. Record fourth quarter adjusted EBITDA(a) was $45.6 million, compared to $43.6 million in the prior year quarter. Balchem Corporation also reported for the full year 2021 net earnings of $96.1 million, compared to net earnings of $84.6 million for 2020. Full year adjusted net earnings were $116.6 million, compared to $107.8 million in the prior year, and full year adjusted EBITDA was $189.8 million, compared to $174.2 million in the prior year.

Balchem Corporation Reports Record Fourth Quarter Sales of $213.1 Million and Net Earnings of $24.9 Million, GAAP EPS of $0.76 and Adjusted EPS of $0.85

NEW HAMPTON, N.Y., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, February 18th at 11:00 AM Eastern Time (ET) to review fourth quarter results. Ted Harris, Chairman of the Board, CEO and President and Martin Bengtsson, CFO will host the call.

Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter Financial Results on February 18, 2022

NEW HAMPTON, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) --  Balchem Corporation (NASDAQ: BCPC) today announced that the Company has been named one of America's Most Responsible Companies by Newsweek magazine. Balchem has earned a ranking amongst this prestigious list of companies for the second consecutive year.

Balchem Corporation Named on Newsweek's 2022 List of America's Most Responsible Companies

New research from Cornell University finds that doubling recommended prenatal choline significantly improved childhood brain performance New research from Cornell University finds that doubling recommended prenatal choline significantly improved childhood brain performance

Groundbreaking Study Reinforces Need for Increased Choline Supplementation During Pregnancy

NEW HAMPTON, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) Chairman of the Board, Chief Executive Officer, and President Ted Harris and Chief Financial Officer Martin Bengtsson will present at the CJS Securities 22nd Annual New Ideas for the New Year Conference on January 12, 2022.

Balchem Corporation to Present at the CJS Securities 22nd Annual New Ideas for the New Year Conference January 12, 2022

ABM Industries

Abbott Labs

Amgen

American Tower

Alexandria Real Estate Equities

AvalonBay Communities

Broadcom

Axis Capital

Baxter

Flanigan's Enterprises

Franklin Resources

Bristol-Myers

Camden National

C.H. Robinson Worldwide

Culp

Calavo Growers

Ecolab

EastGroup Properties

Edison

Eastman Chemical

Ensign Group

Monthly update of the Dividend Champions List. 54 companies declared higher dividends in the past month, with an average increase of 8.71% over their previous payouts.

Dividend Champions For January 2022

Andersons

CubeSmart

Four Corners Property Trust

Hingham Institution for Savings

Kennedy-Wilson Holdings

Lincoln Electric Hlds

MGM Growth Properties

National HealthCare

Nucor

Stryker

TFI International

Toro

Washington Trust Bancorp

W. P. Carey

York Water

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 9.0% and a median increase of 5.4%. I've tracked 524 increases in 2021.

20 Dividend Increases To Finish 2021

NEW HAMPTON, N.Y., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) Chairman of the Board, Chief Executive Officer, and President, Ted Harris and Chief Financial Officer, Martin Bengtsson will participate in the Virtual Stephens Annual Investment Conference on November 29, 2021.

Balchem Corporation to Participate in the Virtual Stephens Annual Investment Conference on November 29, 2021

NEW HAMPTON, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) Chairman of the Board, Chief Executive Officer, and President, Ted Harris and Chief Financial Officer, Martin Bengtsson will present at the Baird 2021 Global Industrial Conference on November 10, 2021. Presentation will be made available on the Balchem website (www.balchem.com/investor-relations/) following the conference.

Balchem Corporation to Participate in the Baird 2021 Global Industrial Conference on November 10, 2021

Balchem Corporation (BCPC) CEO Ted Harris on Q3 2021 Results - Earnings Call Transcript

Balchem Corp (NASDAQ: BCPC) reported third-quarter FY21 sales growth of 13% year-on-year, to $197.87 million, beating the analyst consensus of $196.13 million. Sales from Human Nutrition and Health segment rose 7.3% Y/Y to $111.2 million, Animal Nutrition and Health increased 21.2% to $56.2 million, and Specialty Products grew 20% to $27.6 million.

Balchem Clocks 13% Sales Growth In Q3, Tops Consensus

Balchem (NASDAQ:BCPC) reported its Q3 earnings results on Friday, October 29, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Balchem: Q3 Earnings Insights

NEW HAMPTON, N.Y., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today record third quarter net earnings of $25.0 million for 2021, compared to net earnings of $21.6 million for the third quarter 2020, record third quarter adjusted net earnings(a) of $30.0 million, compared to $26.9 million in the prior year quarter, and record third quarter adjusted EBITDA(a) of $48.3 million, compared to $44.4 million in the prior year quarter.

Balchem Corporation Reports Record Third Quarter Sales of $197.9 Million, Net Earnings of $25.0 Million, GAAP EPS of $0.77, and Adjusted EPS of $0.92

NEW HAMPTON, N.Y., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 29 at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, CEO and President and Martin Bengtsson, CFO will host the call.

Balchem Corporation Announces Quarterly Conference Call for Third Quarter Financial Results on October 29, 2021

Blachem (BCPC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Blachem (BCPC) a New Buy Stock

Balchem Corporation (BCPC) CEO Ted Harris on Q2 2021 Results - Earnings Call Transcript

Shares of Balchem (NASDAQ:BCPC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 9.41% over the past year to $0.93, which beat the estimate of $0.88.

Balchem: Q2 Earnings Insights

NEW HAMPTON, N.Y., July 30, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today record second quarter net earnings of $22.7 million for 2021, compared to net earnings of $21.1 million for the second quarter 2020, adjusted net earnings(a) of $30.4 million, compared to $27.6 million in the prior year quarter, and adjusted EBITDA(a) of $50.1 million, compared to $43.9 million in the prior year quarter.

Balchem Corporation Reports Record Second Quarter Sales of $202.4 Million, Net Earnings of $22.7 Million, GAAP EPS of $0.70, and Adjusted EPS of $0.93

NEW HAMPTON, N.Y., July 28, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) Chairman of the Board, Chief Executive Officer, and President, Ted Harris and Chief Financial Officer, Martin Bengtsson will present at the Jefferies Virtual Industrials Conference on August 4, 2021. Balchem's presentation will begin at 9:00 a.m. (ET).

Balchem Corporation to Present at the Jefferies Virtual Industrials Conference August 4, 2021

NEW HAMPTON, N.Y., July 16, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, July 30 at 11:00 AM Eastern Time (ET) to review second quarter results. Ted Harris, Chairman of the Board, CEO and President, and Martin Bengtsson, CFO will host the call.

Balchem Corporation Announces Quarterly Conference Call for Second Quarter Financial Results on July 30, 2021

Balchem Corporation (BCPC) CEO Ted Harris on Q1 2021 Results - Earnings Call Transcript

Shares of Balchem (NASDAQ:BCPC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 7.41% over the past year to $0.87, which beat the estimate of $0.84.

Balchem: Q1 Earnings Insights

NEW HAMPTON, N.Y., April 30, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today first quarter 2021 net earnings of $23.4 million, compared to net earnings of $19.8 million for the first quarter 2020, adjusted net earnings(a) of $28.4 million, compared to $26.4 million in the prior year quarter, and adjusted EBITDA(a) of $45.7 million, compared to $42.4 million in the prior year quarter.

News for Balchem Stock (BCPC)